ArticleClinical & translational immunology2025

Allogeneic 'off-the-shelf' SARS-CoV-2-specific adoptive T-cell therapy for refractory viral infection and end organ disease.

Andrea S Henden et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.